Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors.

Vantomme V, Dantinne C, Amrani N, Permanne P, Gheysen D, Bruck C, Stoter G, Britten CM, Keilholz U, Lamers CH, Marchand M, Delire M, Guéguen M.

J Immunother. 2004 Mar-Apr;27(2):124-35.

PMID:
14770084
2.

A new tumor-specific antigenic peptide encoded by MAGE-6 is presented to cytolytic T lymphocytes by HLA-Cw16.

Vantomme V, Boël P, De Plaen E, Boon T, van der Bruggen P.

Cancer Immun. 2003 Dec 10;3:17.

3.

CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A.

Jacquemin M, Vantomme V, Buhot C, Lavend'homme R, Burny W, Demotte N, Chaux P, Peerlinck K, Vermylen J, Maillere B, van der Bruggen P, Saint-Remy JM.

Blood. 2003 Feb 15;101(4):1351-8. Epub 2002 Oct 17.

PMID:
12393451
4.

Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.

Chaux P, Luiten R, Demotte N, Vantomme V, Stroobant V, Traversari C, Russo V, Schultz E, Cornelis GR, Boon T, van der Bruggen P.

J Immunol. 1999 Sep 1;163(5):2928-36.

5.

Characterization of the GAGE genes that are expressed in various human cancers and in normal testis.

De Backer O, Arden KC, Boretti M, Vantomme V, De Smet C, Czekay S, Viars CS, De Plaen E, Brasseur F, Chomez P, Van den Eynde B, Boon T, van der Bruggen P.

Cancer Res. 1999 Jul 1;59(13):3157-65.

6.

Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes.

Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P.

J Exp Med. 1999 Mar 1;189(5):767-78.

7.

Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin.

Lee RS, Tartour E, van der Bruggen P, Vantomme V, Joyeux I, Goud B, Fridman WH, Johannes L.

Eur J Immunol. 1998 Sep;28(9):2726-37.

8.

Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer.

Chaux P, Vantomme V, Coulie P, Boon T, van der Bruggen P.

Int J Cancer. 1998 Aug 12;77(4):538-42.

9.

A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma.

Gaugler B, Brouwenstijn N, Vantomme V, Szikora JP, Van der Spek CW, Patard JJ, Boon T, Schrier P, Van den Eynde BJ.

Immunogenetics. 1996;44(5):323-30.

PMID:
8781117

Supplemental Content

Loading ...
Support Center